These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 18930474

  • 1. The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype.
    Kellner M, Muhtz C, Demiralay C, Husemann J, Koelsch W, Yassouridis A, Wiedemann K.
    J Psychiatr Res; 2009 Mar; 43(6):642-8. PubMed ID: 18930474
    [Abstract] [Full Text] [Related]

  • 2. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
    Tõru I, Maron E, Raag M, Vasar V, Nutt DJ, Shlik J.
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):645-52. PubMed ID: 22939006
    [Abstract] [Full Text] [Related]

  • 3. Blunted autonomic reactivity to pharmacological panic challenge under long-term escitalopram treatment in healthy men.
    Agorastos A, Kellner M, Stiedl O, Muhtz C, Wiedemann K, Demiralay C.
    Int J Neuropsychopharmacol; 2014 Dec 11; 18(5):. PubMed ID: 25522396
    [Abstract] [Full Text] [Related]

  • 4. The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study.
    Outhred T, Das P, Dobson-Stone C, Felmingham KL, Bryant RA, Nathan PJ, Malhi GS, Kemp AH.
    Aust N Z J Psychiatry; 2014 Dec 11; 48(12):1115-25. PubMed ID: 24810870
    [Abstract] [Full Text] [Related]

  • 5. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
    Stahl SM, Gergel I, Li D.
    J Clin Psychiatry; 2003 Nov 11; 64(11):1322-7. PubMed ID: 14658946
    [Abstract] [Full Text] [Related]

  • 6. The 5-HTTLPR genotype modulates heart rate variability and its adjustment by pharmacological panic challenge in healthy men.
    Agorastos A, Kellner M, Stiedl O, Muhtz C, Becktepe JS, Wiedemann K, Demiralay C.
    J Psychiatr Res; 2014 Mar 11; 50():51-8. PubMed ID: 24342768
    [Abstract] [Full Text] [Related]

  • 7. Impact of 5-HTTLPR on SSRI serotonin transporter blockade during emotion regulation: A preliminary fMRI study.
    Outhred T, Das P, Dobson-Stone C, Felmingham KL, Bryant RA, Nathan PJ, Malhi GS, Kemp AH.
    J Affect Disord; 2016 May 15; 196():11-9. PubMed ID: 26896742
    [Abstract] [Full Text] [Related]

  • 8. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.
    Won ES, Chang HS, Lee HY, Ham BJ, Lee MS.
    Neuropsychobiology; 2012 May 15; 66(4):221-9. PubMed ID: 23095326
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A.
    Encephale; 2008 Sep 15; 34(4):400-8. PubMed ID: 18922243
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses.
    Nadeem HS, Attenburrow MJ, Cowen PJ.
    Neuropsychopharmacology; 2004 Sep 15; 29(9):1699-703. PubMed ID: 15127082
    [Abstract] [Full Text] [Related]

  • 11. Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo.
    Kreiter D, Drukker M, Mujagic Z, Vork L, Rutten BPF, van Os J, Masclee AAM, Kruimel JW, Leue C.
    J Psychosom Res; 2021 Feb 15; 141():110351. PubMed ID: 33412422
    [Abstract] [Full Text] [Related]

  • 12. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J, Goa KL.
    CNS Drugs; 2003 Feb 15; 17(5):343-62. PubMed ID: 12665392
    [Abstract] [Full Text] [Related]

  • 13. Effects of citalopram and escitalopram on fMRI response to affective stimuli in healthy volunteers selected by serotonin transporter genotype.
    Henry ME, Lauriat TL, Lowen SB, Churchill JH, Hodgkinson CA, Goldman D, Renshaw PF.
    Psychiatry Res; 2013 Sep 30; 213(3):217-24. PubMed ID: 23845563
    [Abstract] [Full Text] [Related]

  • 14. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
    Zwanzger P, Eser D, Aicher S, Schüle C, Baghai TC, Padberg F, Ella R, Möller HJ, Rupprecht R.
    Neuropsychopharmacology; 2003 May 30; 28(5):979-84. PubMed ID: 12700707
    [Abstract] [Full Text] [Related]

  • 15. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder.
    Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J.
    J Psychiatry Neurosci; 1997 Nov 30; 22(5):332-40. PubMed ID: 9401314
    [Abstract] [Full Text] [Related]

  • 16. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
    Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A.
    Biol Psychiatry; 1995 Dec 01; 38(11):742-6. PubMed ID: 8580227
    [Abstract] [Full Text] [Related]

  • 17. No effect of six weeks of treatment with escitalopram on mood in healthy volunteers--irrespective of genotype for the promoter of the serotonin transporter.
    Kellner M, Demiralay C, Muhtz C, Husemann J, Kölsch W, Hiemke C, Yassouridis A, Wiedemann K.
    Psychiatry Res; 2008 Dec 15; 161(3):339-43. PubMed ID: 18962988
    [Abstract] [Full Text] [Related]

  • 18. The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial.
    Zoons E, Tijssen MAJ, Dreissen YEM, Smit M, Booij J.
    Biomolecules; 2020 Jun 08; 10(6):. PubMed ID: 32521736
    [Abstract] [Full Text] [Related]

  • 19. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
    Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ.
    J Clin Psychiatry; 2006 Sep 08; 67(9):1428-34. PubMed ID: 17017830
    [Abstract] [Full Text] [Related]

  • 20. Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study.
    Drueke B, Baetz J, Boecker M, Moeller O, Hiemke C, Gründer G, Gauggel S.
    Psychopharmacology (Berl); 2009 Dec 08; 207(2):213-23. PubMed ID: 19756527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.